Eli Lilly (LLY)

This American pharmaceutical giant commands more than $290 billion in market cap, with products marketed in 120 countries around the world.

Despite the market downturn this year, Eli Lilly is not a beaten-down stock.

In the first six months of 2022, Eli Lilly’s revenue grew 6% year over year. Meanwhile, the company’s adjusted earnings per share improved 12% from a year ago.

Shares are actually up roughly 15% so far in 2022, and Morgan Stanley expects the trend to continue.

On Sept. 7, analyst Terence Flynn reiterated an ‘overweight’ rating on Eli Lilly while raising his price target from $395 to $412.

Considering that Eli Lilly shares trade at around $311 apiece right now, the new price target implies a potential upside of 32%.

Fundrise helps you invest in real estate without having to buy a house. Let their state-of-the-art technology and in-house experience open the door to new opportunities today.

Sign up

Welltower (WELL)

Welltower is in the real estate business.

The company doesn’t own fancy shopping malls or posh office buildings. Instead, it focuses on health care infrastructure and provides real estate capital to senior housing operators, post-acute care providers and health systems.

In Q2, Welltower’s revenue grew 29.1% year over year to $1.47 billion. Its same-store net operating income rose 8.7%.

Health care is a recession-resistant sector, so health care-anchored real estate is typically in high demand.

The company also benefits from a major demographic tailwind: population aging.

Morgan Stanley analyst Ronald Kamdem notes that the population aged 75 and older is expected to grow by 4% annually through 2030, which could serve as a catalyst for Welltower’s business.

Kamdem has an ‘overweight’ rating on the company and a price target of $90 — implying a potential upside of 16%.

Exxon Mobil (XOM)

Thanks to strong oil prices, energy stocks have turned out to be some of the best performers of the S&P 500 so far this year.

Exxon Mobil, for instance, is up 49% year to date — and that’s after a strong rally in 2021.

The oil-producing giant gushes profits and cash flow in this commodity price environment. In the first six months of 2022, Exxon earned $23.3 billion in profits, a huge increase from the $7.4 billion in the year-ago period. Free cash flow totaled $27.7 billion for the first half, compared to $13.8 billion in the same period last year.

Solid financials allow the company to return cash to investors. Exxon pays quarterly dividends of 88 cents per share, translating to an annual yield of 3.7%.

Morgan Stanley analyst Devin McDermott has an ‘overweight’ rating on Exxon and recently raised his price target to $113 — roughly 20% above the current levels.

Pour your portfolio a glass of recession resistance

Fine wine is a sweet comfort in any situation — and now it can make your investment portfolio a little more comfortable, too.

Ownership in real assets like fine wine could be the diversification you need to protect your portfolio against the volatile effects of inflation and recession. High-net-worth investors have kept this secret to themselves for too long.

Now a platform called Vinovest helps everyday buyers invest in fine wines — no sommelier certification required.

Vinovest automatically selects the best wines for your portfolio based on your goals, and it tells you the best times to sell to get the best value for your wine.

About the Author

Jing Pan

Jing Pan

Investment Reporter

Jing is an investment reporter for MoneyWise. Prior to joining the team, he was a research analyst and editor at one of the leading financial publishing companies in North America. An avid advocate of investing for passive income, he wrote a monthly dividend stock newsletter for the better half of the past decade. Jing holds a Master’s Degree in Economics and an Honours Bachelor of Science Degree, both from the University of Toronto.

What to Read Next

Disclaimer

The content provided on MoneyWise is information to help users become financially literate. It is neither tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter.